CytoMed Therapeutics Limited (NASDAQ:GDTC) Shares Shorted: Short Interest Down 43.2% in September

CytoMed Therapeutics Limited (NASDAQ:GDTC) saw a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 3,620 shares, a decline of 43.2% from the August 31st total of 6,370 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 11,046 shares, the short-interest ratio is presently 0.3 days.

CytoMed Therapeutics Price Performance

CytoMed Therapeutics stock opened at $0.90 on Friday. CytoMed Therapeutics has a 52 week low of $0.68 and a 52 week high of $3.68. The company’s 50-day moving average price is $0.90 and its two-hundred day moving average price is $0.98.

CytoMed Therapeutics (NASDAQ:GDTC) last issued its quarterly earnings results on Wednesday, September 30th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $0.06 million for the quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Fundamental Research set a $4.16 price objective on CytoMed Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings restated a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CytoMed Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.16.

About CytoMed Therapeutics

CytoMed Therapeutics Limited is a Singapore-based clinical-stage biotechnology company focused on developing cell-based immunotherapies for cancer. The company’s research centers on using immune cells to recognize and attack tumor cells, with an emphasis on developing treatments that may be suitable for broader use than certain patient-specific therapies.

CytoMed is developing a pipeline of investigational therapies based on technologies involving gamma delta T cells, natural killer T cells and other immune-cell platforms.